Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Aazathioprine / mercaptopurine | Multisystem autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Aazathioprine / mercaptopurine | Multisystem autoimmune disease | Amber protocol | Shared care protocol | West Essex |
| Abatacept | Psoriatic arthritis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Abatacept | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Abrocitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Acamprosate | Alcohol misuse | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Acamprosate | Alcohol misuse | n/a | Patient information | West Essex |
| Acamprosate | Alcohol misuse | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Acamprosate | Alcohol misuse | Amber initiation | Prescribing guideline | West Essex |
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Actinic keratosis | Actinic keratosis | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Uveitis - non-infectious (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Adult ONS in primary care - Quick guide | Nutrition support - Malnutrition | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Aflibercept | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Aflibercept | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
| Agomelatine | Major depressive episodes | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Alemtuzumab | Highly active relapsing remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Alendronic acid | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Alimemazine | All indications, execluding sedation in paediatrics prior to diagnostic scans | Red | Decision document | Hertfordshire and West Essex ICB |
| Alimemazine switch patient letter | Allergy | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Alirocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Aliskiren | Hypertension | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Alitretinoin | Eczema - hand severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Alteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ambrisentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Amikacin | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Anagrelide | Reduction of elevated platelet counts | Red | n/a | Hertfordshire and West Essex ICB |
| Anal fissure | Anal fissure | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Anastrozole | Familial breast cancer | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Andexanet alfa | Reversal of anticoagulation | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Antibiotic toolkit TARGET | Antimicrobial stewardship | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Anticholinergic burden (ACB) | Structured medication review Eclipse Live | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Anticholinergic burden (ACB) | Structured medication review Hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Antihistamine | Seasonal allergic rhinitis - OTC | n/a | Position statement | Hertfordshire and West Essex ICB |
| Antipsychotic depot injections | Schizophrenia | Red | Decision document | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | Atrial fibrillation | Green | n/a | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT and PE | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | VTE prophylaxis following hip and knee surgery | Red | n/a | Hertfordshire and West Essex ICB |
| Apremilast | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Apremilast | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Armour thyroid | Hypothyroidism | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Adults 18 years and over | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Children 5 to 19 years | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Step down guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | MART | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Asthma | Inhaled corticosteroids (ICS) choices | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) adult | Amber protocol | Shared care protocol | West Essex |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Attention deficit hyperactivity disorder (ADHD) | FAQs | n/a | Primary Care prescribing resource | South and West Hertfordshire |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - adult | Amber protocol | Shared care protocol | West Essex |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - children, young people and adults | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol children and young people | Amber protocol | Shared care protocol | West Essex |
| Avatrombopag | Primary chronic immune thrombocytopenia | Red | Decision document | Hertfordshire and West Essex ICB |
| Avatrombopag | Thrombocytopenia in chronic liver disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Aveeno switch patient letter | Emollient | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Axial Spondyloarthritis | Axial Spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Azithromycin | COPD | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Aztreonam lysine | Cystic fibrosis chronic pseudomonas aeruginosa (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Baricitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Baricitinib | Alopecia areata | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Baricitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bath and shower preparations | Dry and pruritic skin conditions | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Bempedoic acid | Primary hypercholesterolaemia or mixed dyslipidaemia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bevacizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
| Bevacizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Bezlotoxumab | Clostridium difficile | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bictegravir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Bile salts malabsorption | Bile salts malabsorption | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Bimekizumab | Axial Spondyloarthritis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Bimekizumab | Psoriatic arthritis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Bimekizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Biologic and Biosimilar Medicines | Where indicated | n/a | Patient information | Hertfordshire and West Essex ICB |
| Biosimilar insulins (Admelog Semglee and Trurapi) | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Bisphosphonates | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose and ketone meters, test strips and lancets | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Bosentan | Digital ulcers and pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Botulinum neurotoxin type A | Sialorrhoea | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Brodalumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Brolucizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Brolucizumab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
| Budesonide - rectal (Budenofalk) | Ulcerative colitis | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Budesonide (Jorveza) | Inducing remission of eosinophilic oesophagitis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Budesonide targeted release (Kinpeygo) | Primary IgA nephrology | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Calcium & vitamin D | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Canagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Cangrelor | Reduction of atherothrombotic events in PCI | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cannabis-based medicinal preparations | Intractable nausea & vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy | Red | Position statement | Hertfordshire and West Essex ICB |
| Care home malnutrition management pathway | Nutrition support - Malnutrition | n/a | Clinical pathways | Hertfordshire and West Essex ICB |
| Care homes - Fortifying food | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
| Care homes - Fridge temperature record | Medication Administration | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Controlled drugs | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Anticoagulation | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Homely remedy and self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Omitted and delayed medicines | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Covert administration | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Good practice guideline | Medicines reconciliation and transfer of care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Care homes - Medication pots poster | Medication Administration | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Care homes & ONS - Relatives and friends information | Nutrition Support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
| Casirivimab plus imdevimab | Covid-19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cefiderocol | Drug-resistant gram-negative bacterial infections severe (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ceftazidime with avibactam | Drug-resistant gram-negative bacterial infections severe (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cenobamate | Focal onset seizures | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Certoliziumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Certolizumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Certolizumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Certolizumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Chlorambucil | Cancer indications | Red | n/a | Hertfordshire and West Essex ICB |
| Chlormethine gel | Mycosis fungoides-type cutaneous T-cell lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cilostazol | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cinacalcet | Secondary Hyperparathyroidism in Adults with End Stage Kidney Disease Requiring Renal Replacement Therapy | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Ciprofibrate | Hypercholesterolaemia | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Cladribine | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Co-careldopa (Carbidopa/levodopa) intestinal gel | Parkinson's disease (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Co-careldopa Intestinal Gel (Duodopa) | Parkinson's Disease (NHSE tertiary centre only) | Red | n/a | Hertfordshire and West Essex ICB |
| Co-proxamol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Colesevelam | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Colesevelam 2nd line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Colestyramine | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Colestyramine 1st line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Colistimethate sodium (Colobreathe) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| COPD | COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| CPCS Community Pharmacy | CPCS Community Pharmacy | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Crohn's disease | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Cytisine | Smoking cessation | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Dalteparin | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
| Dapagliflozin | Heart failure - chronic with preserved or mildly reduced ejection fraction | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dapagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Dapagliflozin | Diabetes type 1 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dapoxetine | Premature ejaculation | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Darbepoetin | Anaemia with chemotherapy (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Darbepoetin | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Daridorexant | Insomnia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Prescribing support document | Hertfordshire and West Essex ICB |
| Darunavir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Darvadstrocel | Complex perianal fistulas in Crohn’s disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dasatinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Deferasirox | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Deferiprone | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Denosumab | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Denosumab Xgeva® | Prevention of skeletal-related events (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dependence forming medicine | Pain - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Desferrioxamine | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Deucravacitinib | Psoriasis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dexamethasone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dexamethasone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) adult | Amber protocol | Shared care protocol | West Essex |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter continuation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
| Dexcom ONE | Diabetes letter initiation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
| Dexcom ONE | Diabetes letter discontinuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter initiation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter continuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes letter self funder (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Dexcom ONE | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Dexcom ONE | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
| Dexcom ONE FAQcs (West Essex) | T1DM | Amber initiation | Patient information | West Essex |
| Dexcom ONE FAQs (Herts) | T1DM | Amber initiation | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Diabetes type 1 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | Diabetic ketoacidosis (DKA) | n/a | Patient information | Hertfordshire and West Essex ICB |
| Dibotermin alfa | Promotion of ectopic bone formation | Red | Decision document | Hertfordshire and West Essex ICB |
| Diclofenac sodium 3% gel | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dienogest | Endometriosis | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Diltiazem ointment 3rd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
| Dimethyl fumarate | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Dipeptidyl peptidase-4 inhibitors (Gliptins) | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - Atrial fibrillation (AF) guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - interactions | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - counselling checklist | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dolutegravir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Domperidone | Nausea vomiting in children | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Donepezil | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Dornase alfa | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Dosulepin | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Doxazosin (prolonged release) | Hypertension, benign prostatic hyperplasia (BPH) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dupilumab | Eosinophilic oesophagitis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dupilumab | chronic rhinosinusitis with nasal polyps | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dupilumab | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Eating & drinking at end of life | Nutrition support - End of life | n/a | Patient information | Hertfordshire and West Essex ICB |
| Eating well - Homemade supplements | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
| Eating well - Quick guide | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
| Eating well for small appetites | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
| Eating, drinking & ageing well | Healthy eating - Older adults | n/a | Patient information | Hertfordshire and West Essex ICB |
| Eclipse Live | Advice and Guidance FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Efavirenz | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Elbasvir | Hepatitis C (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Electronic Cigarettes and other novel nicotine containing products | Tobacco dependance | Red | Position statement | Hertfordshire and West Essex ICB |
| Eltrombopag | Thrombocytopenia related to hepatitis C | Red | Decision document | Hertfordshire and West Essex ICB |
| Eltrombopag | Aplastic anaemia | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Eltrombopag ITP | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Empagliflozin | Chronic kidney disease | Green | Prescribing pathway | Hertfordshire and West Essex ICB |
| Empagliflozin | Heart failure - chronic with preserved or mildly reduced ejection fraction | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Emtricitabine | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| End of life | Anticipatory prescribing guidance v2 | Green | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| End of life | Anticipatory prescribing chart v4 | Green | Primary Care prescribing resource | East and North Hertfordshire, South and West Hertfordshire |
| Enoxaparin | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
| Entecavir | Hepatitis B (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Epoetin | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Epoietin | Anaemia with chemotherapy (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Eptinezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Eptinezumab | Migraine - episodic | Red | Decision document | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Erlotinib | All indications (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Erythropoiesis stimulating agents | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Esketamine | Depression - major | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Etanercept | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Etanercept | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Etanercept | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Etanercept | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Etanercept | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ethosuximide | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Ethosuximide capsules | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Ethosuximide syrup | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Etoposide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Etrasimod | Ulcerative Colitis - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Evolocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Exemestane | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fampridine | Multiple sclerosis (NHSE) | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Faricimab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Faricimab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
| Fentanyl immediate release (IR) | Pain (except for palliative care) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ferric maltol | Iron deficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
| Filgotinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Filgotinib | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Filgotinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Filgrastim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Finerenone | Chronic kidney disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fingolimod | Highly active relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fluocinolone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fluocinolone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fluorouracil 0.5% / Salicylic acid 10% cutaneous solution | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Fondaparinux | Thrombosis | Red | n/a | Hertfordshire and West Essex ICB |
| Fostamatinib | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| FreeStyle Libre | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Fulvestrant | Locally advanced or metastatic breast cancer | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Galantamine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Galcanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Galcanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB, East and North Hertfordshire, South and West Hertfordshire, West Essex |
| Gemfibrozil | Hypercholesterolaemia | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Glatiramer | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Glucosamine and chondroitin | Osteoarthritis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Gluten Free food - Implementation Support | Coeliac disease | n/a | Prescribing guideline | West Essex |
| Gluten Free food - Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | South and West Hertfordshire |
| Gluten free food - Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | East and North Hertfordshire |
| Gluten free food - Prescribing guideline exceptions | Coeliac disease | n/a | Prescribing guideline | East and North Hertfordshire |
| Gluten Free food – Patient information | Coeliac disease | n/a | Patient information | South and West Hertfordshire |
| Gluten Free food – Patient information | Coeliac disease | n/a | Patient information | South and West Hertfordshire |
| Gluten Free food – Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | West Essex |
| Glyceryl trinitrate ointment 2nd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
| Glycopyrronium bromide oral | Hyperhidrosis | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Glycopyrronium bromide oral | Hypersalivation | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Glycopyrronium bromide powder | Inotophoresis for hyperhidrosis | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Golimumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Golimumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Golimumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Golimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Grazoprevir | Hepatitis C (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Guselkumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Guselkumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Hay fever | Hay fever | n/a | Patient information | Hertfordshire and West Essex ICB |
| Herbal treatments and other natural products | All indication | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Homeopathy | All indications | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Hydrocortisone (Plenadren) | Adrenal insufficiency | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Hydroxychloroquine | Rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Hyperhidrosis | Hyperhidrosis - self help | n/a | Patient information | Hertfordshire and West Essex ICB |
| Ibandronic acid - oral | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ibandronic acid IV | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ibrutinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Icosapent ethyl | Hypertriglyceridemia | Red | Decision document | Hertfordshire and West Essex ICB |
| ICS wound care formulary | Wound care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Imatinib | All indications (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Imiquimod 3.75% cream | Actinic keratosis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Imiquimod 5% cream | Actinic keratosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Infections in Primary Care | Infections | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Infliximab IV | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Axial spondyloarthritis - ankylosing spondylitis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV biosimilar | Diarrhoea or colitis associated with Immune Checkpoint Inhibitor therapy | Red | Decision document | Hertfordshire and West Essex ICB |
| Inhaled corticosteroids | Asthma COPD - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Inhaler - environmentally friendly | Asthma COPD | n/a | Patient information | Hertfordshire and West Essex ICB |
| Inhaler reliever | Asthma | n/a | Patient information | Hertfordshire and West Essex ICB |
| Inositol nicotinate | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Inspection - CQC | Managing Medicines in a GP Practice | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Insulin Fiasp | Diabetes type 1 | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Iron chelators | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Isavuconazole | Antifungal (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Ivabradine | stable angina and chronic heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Ivacaftor | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| IVF drugs | Infertility | Red | Decision document | Hertfordshire and West Essex ICB |
| Ixekizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| ixekizumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| ixekizumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Kelhale inhaler | Asthma | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Ketone test strip | Diabetic ketoacidosis (DKA) sick day | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Lamivudine | Hepatitis B (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Lanthanum | Hyperphosphataemia in adult patients with chronic kidney disease | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Laxido | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Lenalidomide | Multiple myeloma follicular lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lenograstim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Letermovir | Cytomegalovirus (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Letrozole | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Linezolid | Antibacterial | Red | Decision document | Hertfordshire and West Essex ICB |
| Lipid management | patient decision aid statin therapy | n/a | Patient information | Hertfordshire and West Essex ICB |
| Lipid management pathway | Statin intolerance | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Lipid management pathway | Primary & secondary prevention | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Liraglutide | Obesity in people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Liraglutide | Overweight and obesity management | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) adult | Amber protocol | Shared care protocol | West Essex |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Lithium | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | Amber protocol | Shared care protocol | West Essex |
| Lithium | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Lithium Primary Care action plan | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Lomitapide | Homozygous familial hypercholesterolaemia (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Long term insomnia management | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
| Low molecular weight heparin (LMWH) | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
| Loxapine | Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lurasidone | Schizophrenia | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Lusutrombopag | Thrombocytopenia in chronic liver disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lutein and Antioxidants | Eye Supplements for AMD | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Macitentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Managing malnutrition - Additional guidance | Nutrition support - Malnutrition | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Mannitol dry powder for inhalation | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mecasermin | Growth failure (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Medication Shortages | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
| Melatonin | Insomnia - Neurodevelopmental Disorders in patients under the age of 18 years | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - Learning disability in adults and paediatrics | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in neurodevelopmental disorders in patients aged 2 to under 18 years | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in adult and paediatric patients with learning disabilities | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia adults excluding learning disabilities | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Melatonin (Slenyto) | Insomnia | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Melphalan | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Memantine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Mesalazine - Octasa preferred 1st choice | Inflammatory bowel disease | Green | n/a | Hertfordshire and West Essex ICB |
| Mesalazine -Mezavant | Inflammatory bowel disease | Double Red | n/a | Hertfordshire and West Essex ICB |
| Mesna | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Metformin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Methotrexate | Autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Methotrexate | Autoimmune disease | Amber protocol | Shared care protocol | West Essex |
| Methotrexate 10mg | Autoimmune disease | Double Red | n/a | Hertfordshire and West Essex ICB |
| Methotrexate 2.5mg | Autoimmune disease | Amber protocol | Prescribing guideline | Hertfordshire and West Essex ICB |
| Methylnaltrexone bromide | Opioid induced bowel dysfunction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Methylnaltrexone bromide | Constipation - opioid induced | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) adult | Amber protocol | Shared care protocol | West Essex |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Metolazone | Oedema | n/a | Patient information | Hertfordshire and West Essex ICB |
| Metolazone | Oedema | Red | Decision document | Hertfordshire and West Essex ICB |
| Mexiletine | Myotonia in non-dystrophic myotonic disorders (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mexiletine | Life threatening ventricular arrhythmias (unlicensed - acute provider only) | Red | Decision document | Hertfordshire and West Essex ICB |
| Migraine | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Migraine | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Minocycline | Acne | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Mirikizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Mitomycin | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Mitotane | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Multi-compartment compliance aid and 7-day prescription guidance | Multi-compartment compliance aid | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Multi-compartment Compliance Aids | Reasonable adjustment | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Multi-compartment Compliance Aids | Assessment tool | n/a | n/a | Hertfordshire and West Essex ICB |
| Multi-compartment Compliance Aids | Patient information | n/a | Patient information | Hertfordshire and West Essex ICB |
| Mycophenolate mofetil | Multisystem autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Mycophenolate mofetil | Multisystem autoimmune disease | Amber protocol | Shared care protocol | West Essex |
| Naftidrofuryl Oxalate | Intermittent claudication in people with peripheral arterial disease | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Naldemedine | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nalmefene | Reduction of alcohol consumption in adult patients who have a high drinking risk level without physical withdrawal risk | Amber initiation | Decision document | West Essex |
| Nalmefene | Reduction of alcohol consumption in adult patients who have a high drinking risk level without physical withdrawal risk | Red | Decision document | East and North Hertfordshire, South and West Hertfordshire |
| Naloxegol | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Naltrexone–bupropion | Overweight and obesity | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nevirapine | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Nicotinic acid | Prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nintedanib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Nirmatrelvir plus ritonavir | Covid-19 (CMDU only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nitazoxanide | Viral hepatitis (B&C) and respiratory syncytial virus (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Obeticholic acid | Primary biliary cholangitis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ocriplasmin | Vitreomacular traction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Omalizumab | Urticaria - severe chronic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Hypertriglyceridaemia - severe | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Opioid | Pain - long-term prescribing for non-cancer, chronic pain in adults | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Opioid | Pain - persistent self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Opioid | Pain - plan agreement | n/a | Patient information | Hertfordshire and West Essex ICB |
| Opioid | Pain - review letter | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Opioid Aware Campaign | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
| Opioid Induced Constipation | Opioid Induced Constipation | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Opioid Prescribing Position Statement | Pain | n/a | Position statement | Hertfordshire and West Essex ICB |
| Opioid reduction | Opioid reduction tool | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Oral nutritional supplement (ONS) review in GP Practice - Supporting Guidance | Nutrition support - Malnutrition | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Oral nutritional supplement (ONS) review in GP practice – Audit Tool | Nutrition support - Malnutrition | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Osteoporosis | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Over The Counter Medicines | Addendum to NHSE | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Over The Counter Medicines (OTC) | NHSE guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Over The Counter Medicines (OTC) | When to prescribe | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Oxycodone and naloxone | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Oxygen | Home oxygen | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Oxygen | Cluster headache | n/a | Decision document | Hertfordshire and West Essex ICB |
| Ozanimod | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | West Essex |
| Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | South and West Hertfordshire |
| Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | East and North Hertfordshire |
| Paediatric cow's milk protein allergy (CMPA) - A guidance document | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - A summary of HCP guidance & resources | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - Advice for breastfeeding mums following a cow's milk free diet | Paediatric Nutrition – CMPA | n/a | Patient information | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - Formula flow chart | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - GP FAQs | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - Managing supplies & when to stop the formula guidance | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paediatric cow's milk protein allergy (CMPA) - Patient FAQs | Paediatric Nutrition – CMPA | n/a | Patient information | Hertfordshire and West Essex ICB |
| Paediatric dietitian pathway – CMPA age 1 year & over | Paediatric Nutrition – CMPA | n/a | Prescribing pathway | South and West Hertfordshire |
| Paediatric dietitian pathway – CMPA age under 1 year | Paediatric Nutrition – CMPA | n/a | Prescribing pathway | South and West Hertfordshire |
| Paediatric faltering growth – Help my child is not eating | Paediatric Nutrition – Faltering Growth | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric faltering growth guidance | Paediatric Nutrition – Faltering Growth | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric formulas table - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric gastro oesophageal reflux guidance | Paediatric Nutrition –GORD | Red | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric preterm infants guidance | Paediatric Nutrition –Preterm | n/a | Decision document | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric product recall - Alimentum & Elecare notification | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric secondary lactose intolerance guidance | Paediatric Nutrition – Lactose Intolerance | Red | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Paediatric specialist formula guidance | Paediatric Nutrition – Infant Formulas | n/a | Prescribing guideline | West Essex |
| Palbociclib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Palforzia | Peanut allergy (Specialist allergy centre) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Palliative care formulary | Palliative care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paracetamol and tramadol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paricalcitol | Hyperparathyroidism (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Patiromer | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Pegfilgrastim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Peginterferon | All indication | Red | Decision document | Hertfordshire and West Essex ICB |
| Pegvisomant | Acromegaly (NHSE tertiary centre only) | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Pentosan polysulfate sodium | Bladder pain syndrome | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Pentoxifylline | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Perindopril arginine | Heart failure, hypertension and prophylaxis of CV events | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Pharmacy First | Pharmacy First | n/a | n/a | Hertfordshire and West Essex ICB |
| Phosphate enema (Cleen) | Constipation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Pigmanorm | Melasma | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Pirfenidone | Idiopathic pulmonary fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Pitolisant | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Posaconazole | Fungal infections (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Position statement - Dessert style ONS | Nutrition support - Malnutrition | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Position statement - ONS & care homes | Nutrition support - Malnutrition | n/a | Position statement | Hertfordshire and West Essex ICB |
| Position statement - ONS & end of life | Nutrition support - End of life | n/a | Position statement | Hertfordshire and West Essex ICB |
| Position Statement - Prescribing nutritional products/vitamin supplements | Nutrition support - Malnutrition & Vitamin insufficiency | n/a | Position statement | Hertfordshire and West Essex ICB |
| Position statement – Diabetic hypo treatment | Diabetes – Hypoglycaemia | n/a | Position statement | South and West Hertfordshire |
| Position statement – Vitamin B compound & compound strong | Vitamin insufficiency | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
| Position statement – Vitamin B compound & compound strong | Vitamin insufficiency | n/a | Prescribing guideline | West Essex |
| Position statement – Vitamin B12 | Vitamin deficiency | n/a | Position statement | South and West Hertfordshire |
| Position statement – Vitamin B12 | Vitamin deficiency | n/a | Position statement | West Essex |
| Position statement – Vitamin D & care homes | Vitamin insufficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Position statement – Vitamin D & inusufficency | Vitamin insufficiency | n/a | Position statement | East and North Hertfordshire |
| Potassium binders | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Prasugrel | Percutaneous coronary intervention (PCI) for treating acute coronary syndromes (ACS) | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Prescription | Private consultation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Prescription - NHSBSA | Organisation and prescriber changes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Prescription - repeat | Clerks hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Prescription - repeat | Prescriber guide with tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Prescription duration | Decision aid | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Prescription duration 7 days | Process and communication for identification | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Prescription duration guidance | Prescription duration guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Probiotics | Treatment or prevention of diarrhoea of any cause. | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Promethazine | All indications | Green | Position statement | Hertfordshire and West Essex ICB |
| Proton pump inhibitors - paediatric | Gastro-protection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Psoriasis | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Psoriatic Arthritis | Psoriatic Arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Qtern | Diabetes type 2 | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Quetiapine | Schizophrenia and bipolar disorder | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Raloxifene | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Raloxifene | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Raltegravir | HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Ranibizumab | Diabetic retinopathy | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ranibizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ranibizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
| RebatesRebates and National Procurement Pricing Agreements | n/a | n/a | Position statement | Hertfordshire and West Essex ICB |
| Reducing medicines waste in care homes - Care home staff | Reducing medicines waste | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Reducing medicines waste in care homes - GP Practice Staff & Prescribers | Reducing medicines waste | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Relugolix | Uterine fibroids | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Rheumatoid Arthritis - moderate | Rheumatoid Arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Rheumatoid Arthritis - severe | Rheumatoid Arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Rifaximin | Hepatic encephalopathy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Riluzole | Amyotrophic Lateral Sclerosis (ALS) form of Motor Neurone Disease (MND) | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine - prevention | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine - treating | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Risankizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Risankizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Risedronate | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ritlecitinib | Alopecia areata - severe | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ritonavir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Rituximab | Autoimmune haemolytic anaemia (AIHA) | Red | Decision document | Hertfordshire and West Essex ICB |
| Rituximab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Rivaroxaban | Prevention of atherothrombotic events in patients after an acute coronary syndrome | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivaroxaban | Preventing atherothrombotic events in people with coronary or peripheral artery disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivastigmine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Roflumilast | COPD | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Romiplostim | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Romosozumab | Osteoporosis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Roxadustat | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Rubefacients, benzydamine, mucopolysaccharide and cooling products (excluding topical NSAIDs and capsaicin) | Musculoskeletal pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ruxolitinib | Polycythaemia vera (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ruxolitinib | Myelofibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sacubitril valsartan | Heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Salamol - letter | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Salamol - poster | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Sarilumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Sayana Press | Contraception | Green | Decision document | Hertfordshire and West Essex ICB |
| Schools | Medicines in schools FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Scriptswitch | Implementation for practices | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| ScriptSwitch | Process simple switches | n/a | Decision document | Hertfordshire and West Essex ICB |
| Secukinumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Secukinumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Secukinumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - adults | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - young people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Diabetes type 2 | n/a | Patient information | Hertfordshire and West Essex ICB |
| Sevelamer | Hyperphosphateemia in adult patients with chronic kidney disease | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| SGLT2 inhibitors | Diabetes type 2 | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Shared care | Attention deficit hyperactivity disorder (ADHD) by Private Provider | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Shared Care | Shared Care Principles | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Shared care | Initiation by a Private Provider | Amber protocol | Patient information | Hertfordshire and West Essex ICB |
| Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Silk garments | Eczema dermatitis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Sodium oxybate | Narcolepsy with cataplexy (tertiary centre only) | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Sodium zirconium | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Solriamfetol | Excessive daytime sleepiness caused by narcolepsy (tertiary centre only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Solriamfetol apnoea | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Somatrogon (Ngenla) | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
| Sotrovimab | Covid-19 (CMDU only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Spacer | Asthma COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Specialist / Non-approved / Non-Formulary Medicines – Information for Patients | Patient information | n/a | Patient information | Hertfordshire and West Essex ICB |
| Specials alternative guidance | Specials alternative guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Statin patient decision aid - NICE | Hypercholesterolaemia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Steroid card | FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Stoma - accessories not for prescribing | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Stoma - accessories not for prescribing | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - adhesive remover spray | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - adhesive remover spray wipes | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - adhesive remover wipes to spray | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - adhesive remover wipes to wipes | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - adhesive spray lotion | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Stoma - adhesive spray lotion | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - Appliance Ordering Information for Patients | Stoma - DAC | n/a | Patient information | Hertfordshire and West Essex ICB |
| Stoma - barrier cream | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - barrier cream | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - barrier ring seal washer | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - barrier ring seal washer | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - collars | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - collars | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - colostomy ileostomy urostomy bag quantities | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - colostomy ileostomy urostomy bag quantities | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - community ostomy service poster | Stoma - DAC | n/a | Prescribing support document | West Essex |
| Stoma - discharge solidifying agent | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - discharge solidifying agent | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - elastic belts | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - elastic belts | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - flange extender retention strip | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - flange extender retention strip | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - gauze swab | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Stoma - gauze swab | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - ICB Prescribing Guidelines for Stoma Appliances | n/a | Position statement | Hertfordshire and West Essex ICB | |
| Stoma - ilex & Orabase | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - Pastes and Fillers | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - pastes and fillers | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - peristomal skin protective foam applicators and wipes | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - peristomal skin protective foam applicators wipes | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - peristomal skin protective sprays | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - powder | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
| Stoma - powder | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - Practical Guide to Stomas for Healthcare Professionals | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Stoma - Practice appliance contractor letter | Stoma - DAC | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Stoma - product samples | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Stoma - product samples | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma - Stoma related surgical procedures | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Stoma - support garments | Stoma | n/a | Position statement | Hertfordshire and West Essex ICB |
| Stoma - support garments | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
| Stoma and continence (appliance and accessories) prescription requests | Stoma - DAC | n/a | Position statement | Hertfordshire and West Essex ICB |
| Stoma Appliance and Accessories Toolkit | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Strontium | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sucroferric Oxyhydroxide | Hyperphosphataemia in adult patients with end stage renal failure requiring renal replacement therapy | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Sulfasalazine | Gastroenterology / Rheumatology | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Sunscreens | Protection against UV radiation (ACBS) | Green | Decision document | Hertfordshire and West Essex ICB |
| Sunscreens | Protection against UV radiation (ACBS) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Tadalafil | Benign prostatic hyperplasia | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tadalafil | Penile rehabilitation | Red | Decision document | Hertfordshire and West Essex ICB |
| Tamoxifen | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tenofovir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Teriflunomide | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Teriparatide | Osteoporosis | Red | Decision document | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | n/a | Patient information | Hertfordshire and West Essex ICB |
| Testosterone gel | Menopause | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Thalidomide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Thickeners & thickened ONS guidance | Dysphagia | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ticagrelor | Preventing atherothrombotic events after myocardial infarction | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tildrakizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Tioguanine | Leukaemia | Red | n/a | Hertfordshire and West Essex ICB |
| Tirbanibulin | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Tirzepatide | Diabetes type 2 | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tixagevimab plus cilgavimab | Covid-19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tobramycin (TOBI Podhaler) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tocilizmuab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Tocilizumab | Covid-19 | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tofacitinib | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Tofacitinib | Axial Spondyloarthritis - ankylosing spondylitis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Tofacitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Tofacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Tolvaptan | Kidney disease - autosomal dominant polycystic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tolvaptan | Hyponatraemia secondary to SIADH | Red | Decision document | Hertfordshire and West Essex ICB |
| Tralokinumab | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Trimipramine | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ulcerative colitis | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ulipristal | Uterine fibroids | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Upadacitinib | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Upadacitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitinib | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitinib | Axial Spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitnib | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Urinary incontinence | Adults | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Urinary Tract Infections (UTI) | Recurrent - adult | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| User guide for Cancelling or Amending eRDs (EMIS and SI) | eRDs | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| User guide for eRD (EMIS and SI) | eRDs | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Ustekinumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ustekinumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ustekinumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ustekinumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Utrogestan | Hormone Replacement Therapy (HRT) | Green | Decision document | Hertfordshire and West Essex ICB |
| Vedolizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Vedolizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Venlafaxine | Depression, anxiety and panic disorders | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Vericiguat | Heart failure - chronic with reduced ejection fraction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Vernakalant | Atrial fibrillation | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Vitamin D - Adult and paediatric deficiency & insufficiency guidance | Vitamin deficiency | n/a | Prescribing guideline | West Essex |
| Vitamin D - Adult deficiency & insufficiency treatment flowchart | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin D - Adult treatment choices | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin D - Care home FAQs | Vitamin deficiency | n/a | Patient information | West Essex |
| Vitamin D - Paediatric treatment choices | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin D - Patient Information 1 | Vitamin deficiency | n/a | Patient information | East and North Hertfordshire |
| Vitamin D - Patient information letter | Vitamin deficiency | n/a | Patient information | West Essex |
| Vitamin D – Adult deficiency & insufficiency guidance | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin D – Paediatric deficiency & insufficiency treatment flowchart | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin D – Patient information 1 | Vitamin deficiency | n/a | Patient information | South and West Hertfordshire |
| Vitamin D – Patient information 2 | Vitamin deficiency | n/a | Patient information | South and West Hertfordshire |
| Vitamin D Patient Information 2 | Vitamin deficiency | n/a | Patient information | East and North Hertfordshire |
| Vitamin prescribing & bariatric surgery | Vitamin insufficiency | n/a | Prescribing guideline | West Essex |
| Vitamin prescribing & private bariatric surgery | Vitamin insufficiency | n/a | Prescribing guideline | South and West Hertfordshire |
| Vitamin prescribing & private bariatric surgery – Patient information | Vitamin insufficiency | n/a | Patient information | South and West Hertfordshire |
| Voriconazole | Chronic pulmonary aspergillosis and fungal infections (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Vortioxetine | Major depressive episodes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Wet AMD | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Zolendronic acid | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |